Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126152131 | 12615213 | 1 | I | 20160710 | 20160715 | 20160802 | 20160802 | PER | US-PFIZER INC-2016348889 | PFIZER | 73.00 | YR | M | Y | 93.44000 | KG | 20160802 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126152131 | 12615213 | 1 | PS | TIKOSYN | DOFETILIDE | 1 | 500 MG, 2X/DAY | 20931 | 500 | MG | CAPSULE, HARD | BID | |||||||
| 126152131 | 12615213 | 2 | SS | TIKOSYN | DOFETILIDE | 1 | 250 UG, 2X/DAY | 20931 | 250 | UG | CAPSULE, HARD | BID | |||||||
| 126152131 | 12615213 | 3 | SS | TIKOSYN | DOFETILIDE | 1 | 250 UG, 2X/DAY | N30314 | 20931 | 250 | UG | CAPSULE, HARD | BID | ||||||
| 126152131 | 12615213 | 4 | SS | TIKOSYN | DOFETILIDE | 1 | 500 UG, 2X/DAY | 20931 | 500 | UG | CAPSULE, HARD | BID | |||||||
| 126152131 | 12615213 | 5 | C | ATORVASTATIN CALCIUM. | ATORVASTATIN CALCIUM | 1 | Oral | 40 MG, 1X/DAY | 0 | 40 | MG | TABLET | QD | ||||||
| 126152131 | 12615213 | 6 | C | COQ 10 | UBIDECARENONE | 1 | 100 MG, 1X/DAY (WITH A MEAL) | 0 | 100 | MG | CAPSULE | QD | |||||||
| 126152131 | 12615213 | 7 | C | VITAMIN D | CHOLECALCIFEROL | 1 | UNK (4000 TABLET AS DIRECTED) | 0 | TABLET | ||||||||||
| 126152131 | 12615213 | 8 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | 20 MG, 1X/DAY (BEFORE BEDTIME) | 0 | 20 | MG | PROLONGED-RELEASE CAPSULE | QD | |||||||
| 126152131 | 12615213 | 9 | C | NIZORAL | KETOCONAZOLE | 1 | UNK, AS NEEDED (ONCE A DAY) | 0 | SHAMPOO | ||||||||||
| 126152131 | 12615213 | 10 | C | ASPIRIN. | ASPIRIN | 1 | 81 MG, 1X/DAY | 0 | 81 | MG | TABLET | QD | |||||||
| 126152131 | 12615213 | 11 | C | NITROGLYCERINE | NITROGLYCERIN | 1 | Sublingual | 0.4 MG, AS NEEDED (LAST USED 2002) | 0 | .4 | MG | TABLET | |||||||
| 126152131 | 12615213 | 12 | C | PULMICORT TURBUHALER | BUDESONIDE | 1 | 1 DF, 2X/DAY (90 MCG/ACT ) | 0 | 1 | DF | BID | ||||||||
| 126152131 | 12615213 | 13 | C | SPIRIVA | TIOTROPIUM BROMIDE MONOHYDRATE | 1 | 2 DF, 1X/DAY (2.5 MCG/ACT ) | 0 | 2 | DF | QD | ||||||||
| 126152131 | 12615213 | 14 | C | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | Oral | 30 MG, 1X/DAY | 0 | 30 | MG | TABLET | QD | ||||||
| 126152131 | 12615213 | 15 | C | WARFARIN SODIUM. | WARFARIN SODIUM | 1 | Oral | 3 MG, 1X/DAY | 0 | 3 | MG | TABLET | QD | ||||||
| 126152131 | 12615213 | 16 | C | CARVEDILOL. | CARVEDILOL | 1 | Oral | 6.25 MG, 2X/DAY | 0 | 6.25 | MG | TABLET | BID | ||||||
| 126152131 | 12615213 | 17 | C | ISOSORBIDE MONONITRATE. | ISOSORBIDE MONONITRATE | 1 | Oral | 30 MG, 1X/DAY | 0 | 30 | MG | MODIFIED-RELEASE TABLET | QD | ||||||
| 126152131 | 12615213 | 18 | C | FUROSEMIDE. | FUROSEMIDE | 1 | Oral | 20 MG, 1X/DAY, (EACH MORNING) | 0 | 20 | MG | TABLET | QD | ||||||
| 126152131 | 12615213 | 19 | C | ENTRESTO | SACUBITRILVALSARTAN | 1 | Oral | UNK, 2X/DAY, (SACUBITRIL 49MG /VALSARTAN 51 MG) | 0 | 1 | DF | TABLET | BID | ||||||
| 126152131 | 12615213 | 20 | C | SPIRONOLACTONE. | SPIRONOLACTONE | 1 | Oral | 25 MG, 1X/DAY | 0 | 25 | MG | TABLET | QD | ||||||
| 126152131 | 12615213 | 21 | C | KLOR-CON | POTASSIUM CHLORIDE | 1 | Oral | 10 UG, 2X/DAY | 0 | 10 | UG | PROLONGED-RELEASE TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126152131 | 12615213 | 1 | Atrial fibrillation |
| 126152131 | 12615213 | 2 | Cardiac disorder |
| 126152131 | 12615213 | 5 | Type V hyperlipidaemia |
| 126152131 | 12615213 | 14 | Atrial fibrillation |
| 126152131 | 12615213 | 16 | Ischaemic cardiomyopathy |
| 126152131 | 12615213 | 17 | Ischaemic cardiomyopathy |
| 126152131 | 12615213 | 18 | Ischaemic cardiomyopathy |
| 126152131 | 12615213 | 19 | Ischaemic cardiomyopathy |
| 126152131 | 12615213 | 20 | Ischaemic cardiomyopathy |
| 126152131 | 12615213 | 21 | Ischaemic cardiomyopathy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126152131 | 12615213 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126152131 | 12615213 | Drug effect incomplete | |
| 126152131 | 12615213 | Heart rate increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126152131 | 12615213 | 3 | 201603 | 0 | ||
| 126152131 | 12615213 | 11 | 2002 | 0 |